Investors would be wise to get out now while there's still time.
On the basis of improving cash flow and positive clinical trial data, these shares should reach $135 in the next six to 12 months.
Nokia doesn't need a miracle. It just needs profits.
The company must develop a stronger presence in the enterprise for these shares to work in the long term.
As long as Covidien stock remains under $97 per share, it's a buy.
Visa's long-term story hasn't changed but there is no compelling reason to own this stock.
Investors are discounting AT&T in several critical areas. They are wrong.
Nadella has already executed his hardest task -- changing the market's perception of what Microsoft is and what it can be.
The expected earnings from VMware's growth may never materialize because VMware's market is rapidly changing.
On the basis of long-term margin expansion and 3% to 4% volume growth, these shares should trade at $46 by the end of the year.